

PRODUCT SPECIFICATION

STATENS
SERUM
INSTITUT



HYB 332-01 Anti Δ Lys β_2 -microglobulin

Mouse monoclonal antibody

Article No.	55505 (0.2 mL), 101077 (1.0 mL)																
Product Name	HYB 332-01 Anti Δ Lys β_2 -microglobulin																
Clone	10B5																
Subclass	IgG1/kappa																
Description	Preparation:	Protein-A purified															
	Concentration:	1 mg/mL \pm 10%, based on A_{280} . See Certificate of Analysis for details.															
	Solvent:	PBS, pH 7.2 – 7.4															
	Storage:	-18 °C or colder															
Antigen	DesLys-58 β_2 -microglobulin (Δ Lys β_2 -microglobulin or Δ K58- β_2 M) is a modified form of β_2 -microglobulin lacking the lysine residue at position 58. This modified form has been shown to be associated with chronic inflammatory conditions (1) and may be implicated in dialysis-related amyloidosis (2). In contrast to native β_2 M, Δ K58- β_2 M binds to a hitherto unknown cell surface receptor independent of classical MHC class I molecules (3).																
Immunogen	Peptide conjugated to S3. The synthetic peptide corresponds to amino acid residues 49-57 of the β_2 -microglobulin with an N-terminal cysteine residue added: H-CVEHSDLSFS-OH																
Specificity	The antibody is specific for desLys-58 β_2 -microglobulin (Δ K58- β_2 M).																
Epitope Specificity	This monoclonal antibody as well the other monoclonal antibodies developed in this series all have the same epitope specificity.																
Reactivity	HYB 332-01 Anti Δ Lys β_2 -microglobulin reacts with Δ K58- β_2 M in indirect ELISA and it reacts with Δ K58- β_2 M in a capture ELISA using a polyclonal anti- β_2 -microglobulin antibody to capture native β_2 M or the Δ K58- β_2 M (3, 6). In western blot, HYB 332-01 Anti Δ Lys β_2 -microglobulin reacts only with Δ K58- β_2 M and not with native β_2 M (3).																
Culture Medium	Dulbecco's modified Eagle's medium with 10% fetal calf serum.																
Fusion Partner	X63-Ag8.653.																
Immunization	Female NMRI mice were immunized i.p. with immunogen.																
Application	<table><thead><tr><th>Method</th><th>Usability</th><th>References</th></tr></thead><tbody><tr><td>ELISA</td><td>yes</td><td>4-5</td></tr><tr><td>FACS</td><td>yes</td><td>3, 6</td></tr><tr><td>Immunoblotting</td><td>yes</td><td>3</td></tr><tr><td>Immunofluorescence</td><td>nd.</td><td></td></tr></tbody></table>	Method	Usability	References	ELISA	yes	4-5	FACS	yes	3, 6	Immunoblotting	yes	3	Immunofluorescence	nd.		
Method	Usability	References															
ELISA	yes	4-5															
FACS	yes	3, 6															
Immunoblotting	yes	3															
Immunofluorescence	nd.																

See next page

HYB 332-01 Anti Δ Lys β 2-microglobulin

mouse monoclonal antibody

STATENS
SERUM
INSTITUT



References

- 1) **Nissen, M.H.** (1993) Proteolytic modification of β_2 -microglobulin in human serum. Danish Med. Bul., 40, 56-64.
- 2) **Heegaard, N.H.H., Roepstorff, P., Molberg, S.G. and Nissen, M.H.** (2002) Cleaved β_2 -microglobulin partially attains a conformation that has amyloidogenic features. J. Biol. Chem. 277, 11184-11189.
- 3) **Wang, M., Corlin, D.B., Heegaard, N.H.H., Claesson, M.H. et al.** (2007) Cellular expression or binding of desLys58- β_2 -microglobulin is not dependent on the presence of the tri-molecular MHC class I complex. Scand. J. Immunol. 67, 105-112.
- 4) **Corlin, D.B., Sen, J.W., Ladefoged, S., Lund, G.B. et al.** (2005) Quantification of cleaved β_2 - microglobulin in serum from patients undergoing chronic hemodialysis. Clin. Chem. 51, 1177-1184.
- 5) Editorials: **James F. Winchester** (2005) Novel changes in β_2 -microglobulin in dialysis patients Clin Chem. 51, 1089-1090.
- 6) **Wang M, Harhaji L, Lamberth K, Harndahl M, Buus S, Heegaard NH, Claesson MH, Nissen MH** (2009) Modified human beta 2-microglobulin (desLys(58)) displays decreased affinity for the heavy chain of MHC class I and induces nitric oxide production and apoptosis. Scand J Immunol. 69, 203-12.

Conditions

For research use only. Not for use in diagnostic procedures. Not for therapeutic use or applications.

The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall Statens Serum Institut be responsible for loss of profits or indirect consequential losses resulting from use of its products. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.